Journal of diabetes science and technology
Dec 26, 2024
The use of artificial intelligence (AI) in diabetes management is emerging as a promising solution to improve the monitoring and personalization of therapies. However, the integration of such technologies in the clinical setting poses significant cha...
Journal of diabetes science and technology
Nov 22, 2024
Artificial intelligence (AI) is increasingly being used to diagnose complications of diabetes. Artificial intelligence is technology that enables computers and machines to simulate human intelligence and solve complicated problems. In this article, w...
Journal of diabetes science and technology
Feb 25, 2024
During an artificial intelligence (AI)-assisted diabetic retinopathy screening event, we performed a survey on patients´ perceptions on AI. Respondents were individuals with diabetes, mostly followed in primary healthcare with a low education level. ...
Journal of diabetes science and technology
Dec 4, 2023
BACKGROUND: The use of machine learning and deep learning techniques in the research on diabetes has garnered attention in recent times. Nonetheless, few studies offer a thorough picture of the knowledge generation landscape in this field. To address...
Journal of diabetes science and technology
Aug 29, 2023
BACKGROUND: To compare the performance of Medios (offline) and EyeArt (online) artificial intelligence (AI) algorithms for detecting diabetic retinopathy (DR) on images captured using fundus-on-smartphone photography in a remote outreach field settin...
Journal of diabetes science and technology
Jan 11, 2023
BACKGROUND: The Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) study demonstrated continuous glucose monitoring (CGM) reduced hypoglycemia over 6 months among older adults with type 1 diabetes (T1D) compared with blood glucose monitor...
Journal of diabetes science and technology
Dec 23, 2022
BACKGROUND: Real-world studies of people with type 2 diabetes (T2D) have shown insufficient dose adjustment during basal insulin titration in clinical practice leading to suboptimal treatment. Thus, 60% of people with T2D treated with insulin do not ...